Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes - Aix-Marseille Université Access content directly
Journal Articles Jto Clinical and Research Reports Year : 2020

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

1 GRC 4 - Theranoscan - Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules
2 CHU Tenon [AP-HP]
3 HUS - Laboratoire de Biochimie et Biologie Moléculaire [Strasbourg]
4 IRFAC - Inserm U1113 - Interface de Recherche Fondamentale et Appliquée en Cancérologie
5 GHRMSA - Groupe hospitalier de la région de Mulhouse Sud-Alsace
6 INP - Institut de neurophysiopathologie
7 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
8 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
9 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
10 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
11 Service Pneumologie-Allergologie [CHU Toulouse]
12 GHE - Groupement Hospitalier Lyon-Est
13 CHIC - Centre Hospitalier Intercommunal de Créteil
14 Institut de Biochimie et Biologie Moléculaire [CHRU Lille]
15 OSS - Oncogenesis, Stress, Signaling
16 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
17 INSERM U1053, Université Bordeaux, Bordeaux, France.
18 CHU Clermont-Ferrand
19 INSERM UMR S1193
20 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
21 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
22 IFCT - Intergroupe Francophone de Cancérologie Thoracique [Paris]
23 Service de pneumologie [Centre Hospitalier Lyon Sud - HCL]
24 Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
25 Service de pneumologie [CHU Cochin]
26 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers

Abstract

Introduction - Methods - In the Biomarkers France study, 4894 mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the mutations subtype. Results - Over 95% of patients with mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common mutation subtype was G12C (374 patients; 41.5%), followed by G12V (168; 18.6%), G12D (131; 14.5%), G12A (62; 6.9%), G13C (45; 5.0%), G13D (31; 3.4%), and others (10; 1%). Approximately 21% of patients had transition mutation and 68.2% had a transversion mutation. G12D and transition mutations were predominant in never-smokers. The median overall survival for patients with -mutated NSCLC was 8.1 months (95% confidence interval [CI]: 7.5-9.5), without any differences according to the different subtypes mutations. The median progression-free survival was 4.6 months (95% CI: 4.2-5.1) for first-line treatment and 4.8 months (95% CI: 4.3-6.8) for second-line treatment, without any differences according to the different subtypes mutations. Conclusions -

Domains

Cancer
Fichier principal
Vignette du fichier
PIIS2666364320300576.pdf (940.69 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03430888 , version 1 (16-11-2021)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

Anne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, L'Houcine Ouafik, Virginie Westeel, et al.. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. Jto Clinical and Research Reports, 2020, 1 (3), pp.100052. ⟨10.1016/j.jtocrr.2020.100052⟩. ⟨hal-03430888⟩
86 View
32 Download

Altmetric

Share

Gmail Facebook X LinkedIn More